JP2013530685A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013530685A5 JP2013530685A5 JP2013511417A JP2013511417A JP2013530685A5 JP 2013530685 A5 JP2013530685 A5 JP 2013530685A5 JP 2013511417 A JP2013511417 A JP 2013511417A JP 2013511417 A JP2013511417 A JP 2013511417A JP 2013530685 A5 JP2013530685 A5 JP 2013530685A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- oligoribonucleotide
- pharmaceutical composition
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091027075 5S-rRNA precursor Proteins 0.000 claims description 47
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 239000002773 nucleotide Substances 0.000 claims description 25
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 108020004459 Small interfering RNA Proteins 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 229940127089 cytotoxic agent Drugs 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 230000008685 targeting Effects 0.000 claims description 9
- 210000004881 tumor cell Anatomy 0.000 claims description 9
- 108091034117 Oligonucleotide Proteins 0.000 claims description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 239000002502 liposome Substances 0.000 claims description 8
- 239000002105 nanoparticle Substances 0.000 claims description 8
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 6
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 6
- 239000004055 small Interfering RNA Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 230000004614 tumor growth Effects 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 108091028664 Ribonucleotide Proteins 0.000 claims description 3
- 239000002336 ribonucleotide Substances 0.000 claims description 3
- 230000004565 tumor cell growth Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 229920001523 phosphate polymer Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 3
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 125000002796 nucleotidyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 4
- 101001033728 Homo sapiens Histone-lysine N-methyltransferase MECOM Proteins 0.000 description 4
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34710410P | 2010-05-21 | 2010-05-21 | |
| US61/347,104 | 2010-05-21 | ||
| PCT/US2011/037609 WO2011146938A1 (en) | 2010-05-21 | 2011-05-23 | Reagents and methods for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016139258A Division JP2016180011A (ja) | 2010-05-21 | 2016-07-14 | がんを治療するための試薬および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013530685A JP2013530685A (ja) | 2013-08-01 |
| JP2013530685A5 true JP2013530685A5 (enExample) | 2014-07-10 |
| JP6033218B2 JP6033218B2 (ja) | 2016-11-30 |
Family
ID=44121362
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013511417A Expired - Fee Related JP6033218B2 (ja) | 2010-05-21 | 2011-05-23 | がんを治療するための試薬および方法 |
| JP2016139258A Pending JP2016180011A (ja) | 2010-05-21 | 2016-07-14 | がんを治療するための試薬および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016139258A Pending JP2016180011A (ja) | 2010-05-21 | 2016-07-14 | がんを治療するための試薬および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9273316B2 (enExample) |
| EP (2) | EP2571987B1 (enExample) |
| JP (2) | JP6033218B2 (enExample) |
| AU (1) | AU2011255203B2 (enExample) |
| CA (1) | CA2800065A1 (enExample) |
| WO (1) | WO2011146938A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG190466A1 (en) * | 2011-11-18 | 2013-06-28 | Agency Science Tech & Res | Methods for diagnosis and/or prognosis of ovarian cancer |
| WO2017156252A1 (en) * | 2016-03-10 | 2017-09-14 | President And Fellows Of Harvard College | Biosynthetic modules |
| EP3426598B1 (en) | 2016-03-11 | 2021-07-28 | Children's Medical Center Corporation | Nucleic acid nanoswitch catenanes |
| EP3494124B1 (en) | 2016-08-02 | 2022-03-09 | President and Fellows of Harvard College | Crisscross cooperative self-assembly |
| JP2022545055A (ja) * | 2019-07-09 | 2022-10-25 | アライズ プレシジョン メディシン，インク． | ＰＲＤＭ１４タンパク質の発現をダウンレギュレートする標的化ｓｉＲＮＡ製剤を使用する癌処置 |
| CN116113421A (zh) | 2020-05-14 | 2023-05-12 | 阿莱兹精准医疗公司 | 使用siRNA调节PRDM2/RIZ蛋白表达的癌症治疗 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| CA1310924C (en) | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Infective drug delivery system |
| US4970154A (en) | 1987-10-09 | 1990-11-13 | Baylor College Of Medicine | Method for inserting foreign genes into cells using pulsed radiofrequency |
| US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| US5672510A (en) | 1990-01-19 | 1997-09-30 | Genetic Therapy, Inc. | Retroviral vectors |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| US5902880A (en) | 1994-08-19 | 1999-05-11 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US6146886A (en) | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
| US5484720A (en) | 1994-09-08 | 1996-01-16 | Genentech, Inc. | Methods for calcium phosphate transfection |
| CA2207593A1 (en) | 1994-12-13 | 1996-06-20 | John Gustofson | Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses |
| EP0832269A1 (en) | 1995-06-07 | 1998-04-01 | Baylor College Of Medicine | Nucleic acid transporters for delivery of nucleic acids into a cell |
| US5837854A (en) * | 1996-04-05 | 1998-11-17 | University Of Massachusetts | Oligonucleotides with anti-Epstein-Barr virus activity |
| US5679559A (en) | 1996-07-03 | 1997-10-21 | University Of Utah Research Foundation | Cationic polymer and lipoprotein-containing system for gene delivery |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| WO1999004819A1 (en) | 1997-07-24 | 1999-02-04 | Inex Pharmaceuticals Corporation | Liposomal compositions for the delivery of nucleic acid catalysts |
| AR013269A1 (es) | 1997-08-04 | 2000-12-13 | Scras | Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral |
| CA2315256A1 (en) | 1997-12-16 | 1999-06-24 | Valentis, Inc. | Needle-free injection of formulated nucleic acid molecules |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| DE60040274D1 (de) | 1999-03-10 | 2008-10-30 | Phogen Ltd | Verabreichung von nukleinsäuren und proteinen an zellen |
| WO2001025422A2 (en) * | 1999-10-07 | 2001-04-12 | Avi Biopharma, Inc. | Antisense compositions and cancer-treatment methods |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| WO2005116204A1 (ja) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| JP2009511613A (ja) | 2005-10-17 | 2009-03-19 | エンカム ファーマシューティカルズ アクティーゼルスカブ | 神経細胞接着分子ｌ１のペプチド断片を含む新規ｆｇｆ受容体結合化合物 |
| US20100119529A1 (en) | 2006-05-12 | 2010-05-13 | Furgeson Darin Y | Elastin-like polymer delivery vehicles |
| JP5307708B2 (ja) * | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| WO2013180295A1 (ja) | 2012-06-01 | 2013-12-05 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
| US9507178B1 (en) | 2013-08-29 | 2016-11-29 | Charles Wesley Blackledge | Electromagnetic waveguide assembly |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2011
- 2011-05-23 CA CA2800065A patent/CA2800065A1/en not_active Abandoned
- 2011-05-23 US US13/113,963 patent/US9273316B2/en active Active
- 2011-05-23 EP EP11722271.1A patent/EP2571987B1/en not_active Not-in-force
- 2011-05-23 JP JP2013511417A patent/JP6033218B2/ja not_active Expired - Fee Related
- 2011-05-23 AU AU2011255203A patent/AU2011255203B2/en not_active Ceased
- 2011-05-23 EP EP17156698.7A patent/EP3190187A1/en not_active Withdrawn
- 2011-05-23 WO PCT/US2011/037609 patent/WO2011146938A1/en not_active Ceased
-
2016
- 2016-01-22 US US15/004,359 patent/US20160362693A1/en not_active Abandoned
- 2016-07-14 JP JP2016139258A patent/JP2016180011A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260069625A1 (en) | Organic compositions to treat kras-related diseases | |
| CN107106591B (zh) | 用于gst-pi基因调节的rna干扰剂 | |
| JP2013530685A5 (enExample) | ||
| TWI752927B (zh) | 具高活性及減低脫靶之siRNA構造 | |
| CA2605068A1 (en) | Delivery of sirna by neutral lipid compositions | |
| US20210244826A1 (en) | Short interfering rna templated lipoprotein particles (sirna-tlp) | |
| Dhuri et al. | Therapeutic potential of chemically modified, synthetic, triplex peptide nucleic acid–based oncomir inhibitors for cancer therapy | |
| CN115315514B (zh) | 具有核苷类似物的寡核苷酸 | |
| JP2019196384A (ja) | ＮＯＴＣＨ １特異的なｓｉＲＮＡ分子 | |
| Keyvani et al. | Insight into RNA-based therapies for ovarian cancer | |
| EP4025696A1 (en) | Chimeric complex and therapeutic uses thereof | |
| EP3902917A2 (en) | Compositions and methods for treating cancer | |
| Mokhlis et al. | Nanoparticle delivery of miRNA in cancer | |
| US20250354156A1 (en) | Compositions and Methods for Treating Cancer | |
| EP4396347B1 (en) | Chimeric complex and therapeutic uses thereof | |
| Class et al. | Patent application title: SHORT INTERFERING RNA TEMPLATED LIPOPROTEIN PARTICLES (SIRNA-TLP) | |
| CA3174172A1 (en) | Compositions and methods for treating cancer | |
| CN121057576A (zh) | 用于皮肤递送治疗性寡核苷酸的树突状缀合物 | |
| Xiao | Peptide Conjugated Lipid Nanoparticles for Anti-Cancer Drug Delivery. | |
| Phei Er | Liposome-based nanovehicles for cancer therapy | |
| Schmitz et al. | Pharmacokinetics Of Nucleic‐Acid‐Based Therapeutics | |
| WO2020153503A1 (ja) | ＳＮＨＧ１２遺伝子に由来するｎｃＲＮＡの発現抑制剤を有効成分とするがん増殖抑制剤 |